W. L. Gore & Associates (Gore) reported the first clinical uses in Australia of the GORE C3 Delivery System to deploy the GORE EXCLUDER AAA Endoprosthesis as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA). The recent procedures were successfully performed by vascular surgeons at medical centers of excellence around Australia. This game-changing new technology represents a leap forward in medical innovation by allowing physicians to position the device to the specific anatomy of each individual patient.

“The new system allowed us to reposition the GORE EXCLUDER Device to support cannulation of the contralateral gate. Deployment of the device remains straightforward and easy to use and provides us with greater control, as well as positioning flexibility, during the procedure.”

The GORE C3 Delivery System provides the clinician with the ability to reposition the GORE EXCLUDER Device prior to final release from the delivery catheter. The added deployment control provides physicians increased confidence in treating challenging anatomies, as well as cannulation options with the ability to bring the contralateral gate to the contralateral guidewire. Once delivered into the aorta, the GORE C3 Delivery System uniquely and intuitively enables repositioning of the stent-graft. The ability to reposition the device can minimize complications that could occur if the graft needs to be repositioned after the initial deployment.

The first Australian procedures to treat patients with an AAA using the new system were performed by:

* Geoff White, MD and Gavin O’Brien, MD, Royal Prince Alfred Hospital, Camperdown

* Marek Garbowski, MD and Lorraine Corfield, MD, Sir Charles Gairdner Hospital, Perth

According to Professor White, Royal Prince Alfred Hospital, a 72-year-old male with an abdominal aneurysm successfully received the first GORE EXCLUDER AAA Endoprosthesis featuring C3 Delivery System in Australia. “The new system allowed us to reposition the GORE EXCLUDER Device to support cannulation of the contralateral gate. Deployment of the device remains straightforward and easy to use and provides us with greater control, as well as positioning flexibility, during the procedure.”

Mr. Garbowski, Sir Charles Gairdner Hospital, Perth, commented, “We used the unique ability to reposition the GORE EXCLUDER Device, increasing our proximal placement accuracy beyond what would have been possible with a single deployment. This feature will increase our confidence in treating challenging aortic neck anatomies.”

The GORE EXCLUDER Device remains virtually unchanged, maintaining the same low delivery profile and flexibility on catheter that facilitates access and passage through narrow and tortuous anatomies. Once delivered into the aorta, the GORE C3 Delivery System uniquely and intuitively enables repositioning of the stent-graft during the procedure. The ability to reposition the device may minimize complications that could occur if the graft needs to be repositioned after the initial deployment. This revolutionary technology was designed to give physicians a second or third opportunity to accurately place the stent graft relative to the patient’s anatomy.

More than 112,000 GORE EXCLUDER Devices have been distributed worldwide since 1997. The GORE EXCLUDER AAA Endoprosthesis is constructed of a durable ePTFE bifurcated graft with an outer self-expanding nitinol support structure which provides both device flexibility and material durability. The function of the endoprosthesis is to internally reline the abdominal aorta, including the bifurcation, and isolate the aneurysm from blood circulation. The device is inserted by a catheter-based delivery technique through small incisions in the patient’s legs.

Products listed may not be available in all markets. GORE®, C3, EXCLUDER®, and designs are trademarks of W. L. Gore & Associates.

Source:
W. L. Gore & Associates